English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The purpose of the research was to develop a prescribing of immunomodulators Imudon, Viferon, Superlymph in the complex treatment of frequently ill children (FIC) with a frequency of ARI 6 or more times a year, foci of chronic infection in oro and nasopharynx, and intermittent (seasonal) AR mild or moderate severity (SAR). Methods: 120 FIC from 5 to 7 years old (56 boys and 64 girls) were followedup during 2 years. Investigation revealed pollen and household allergens predomination in the spectrum of causesignificant allergens. Microbial landscape of chronic infection foci in the oro and nasopharynx was characterized by a predominance of Staphylococcus aureus in 71,2%, Candida albicans in 28,8%, Streptococcus haemolyticus in 50% of patients. In 67.4% of patients microbial associations of 2 and 3 pathogens predominated. Immune system abnormalities were characterized by reduction in T cells, the level of serum IgA in 62.5%, gammaIFN – in 80%, alphainterferon – a 60% increase in serum IgG – at 62,5%, TNFα – 80,0%, and IgE – in 100% of the children. Supplementation of Imudon, Superlymph and Viferon as a component of complex treatment of this category of children reduces the mucous contamination with active forms of Candida albicans by 24 times, with bacterial flora ( Staphylococcus aureus, Streptococcus spp. ) in 2 3,4 times, reduces inflammation of the mucous membranes of oro and nasopharynx, adenoid hypertrophy, reduces the frequency of ARI in 1,9, 2,5 and 3,1 times respectively. In 16,6% of FIC with SAR who did not receive immunomodulators in complex treatment, persistent AR developed in a year of observation. Cases of persistent AR in groups of children receiving Superlymph or Viferon were not revealed.

IMMUNOTROPIC AGENTS IN COMPLEX TREATMENT OF CHILDREN WITH INTERMITTENT ALLERGIC RHINITIS AND RECURRENT RESPIRATORY INFECTIONS